Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 studyResearch in context

• Main Authors: Xiaoling Cai (Author), Linong Ji (Author), Mingxia Yuan (Author), Jianhua Ma (Author), Fang Bian (Author), Sheli Li (Author), Wuyan Pang (Author), Shuang Yan (Author), Huimin Zhou (Author), Minghui Hou (Author), Wenhui Li (Author), Ying Jia (Author), Li Liu (Author), Ke Ding (Author), Michael Xu (Author)
• Format: Book
• Published: Elsevier, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Visepegenatide, a once-weekly glucagon-like peptide-1 receptor agonist injection, demonstrated effective glycaemic control and good tolerability without the requirement of dose titration in the two completed phase 2 studies. We aimed to evaluate the efficacy and safety of visepe...